CL2011000098A1 - Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria. - Google Patents

Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.

Info

Publication number
CL2011000098A1
CL2011000098A1 CL2011000098A CL2011000098A CL2011000098A1 CL 2011000098 A1 CL2011000098 A1 CL 2011000098A1 CL 2011000098 A CL2011000098 A CL 2011000098A CL 2011000098 A CL2011000098 A CL 2011000098A CL 2011000098 A1 CL2011000098 A1 CL 2011000098A1
Authority
CL
Chile
Prior art keywords
betadefensin
mammalian
inflammatory disease
treat inflammatory
treat
Prior art date
Application number
CL2011000098A
Other languages
English (en)
Spanish (es)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holsebrinch Karoline Sidelmann Mygin
Soeren Kjaerulff
Birgitt Andersen
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of CL2011000098A1 publication Critical patent/CL2011000098A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2011000098A 2008-07-18 2011-01-17 Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria. CL2011000098A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
EP09160448 2009-05-15

Publications (1)

Publication Number Publication Date
CL2011000098A1 true CL2011000098A1 (es) 2011-10-07

Family

ID=41445843

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000098A CL2011000098A1 (es) 2008-07-18 2011-01-17 Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.

Country Status (18)

Country Link
US (1) US20100016232A1 (ru)
EP (1) EP2320929B1 (ru)
JP (1) JP2011528332A (ru)
KR (2) KR20110031962A (ru)
CN (1) CN102159232A (ru)
AP (1) AP2011005537A0 (ru)
AR (1) AR072524A1 (ru)
AU (1) AU2009272680A1 (ru)
BR (1) BRPI0915780A2 (ru)
CA (1) CA2730674A1 (ru)
CL (1) CL2011000098A1 (ru)
EA (1) EA201170218A1 (ru)
IL (1) IL210714A0 (ru)
MX (1) MX2011000569A (ru)
NZ (1) NZ590466A (ru)
TW (1) TW201004641A (ru)
WO (1) WO2010007165A2 (ru)
ZA (1) ZA201100462B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110092325A (ko) 2008-07-18 2011-08-17 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증성 장질환의 치료
WO2010007168A2 (en) * 2008-07-18 2010-01-21 Novozymes A/S Treatment of rheumatoid arthritis with mammal beta defensins
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
KR101249702B1 (ko) * 2010-06-16 2013-04-05 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CN107362171A (zh) * 2011-04-15 2017-11-21 海洋聚合物技术公司 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
JP6151981B2 (ja) * 2013-06-18 2017-06-21 一般社団法人健康科学リソースセンター 関節リウマチ患者における生物学的製剤の有効性の予測方法
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
EP3448409A1 (en) 2016-04-29 2019-03-06 Defensin Therapeutics ApS Treatment of liver, biliary tract and pancreatic disorders
AU2017376400A1 (en) 2016-12-13 2019-06-20 Novozymes A/S Methods for treating inflammatory conditions of the lungs
KR102631542B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102631543B1 (ko) 2018-03-14 2024-02-01 서울대학교산학협력단 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도
WO2020046002A1 (ko) * 2018-08-31 2020-03-05 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
WO2023144701A1 (en) 2022-01-28 2023-08-03 Johnson & Johnson Consumer Inc. Biomarkers predictive of atopic dermatitis
WO2023194839A1 (en) 2022-04-04 2023-10-12 Donnelly Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
AU2008297551A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent
KR20110092325A (ko) * 2008-07-18 2011-08-17 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증성 장질환의 치료
WO2010007168A2 (en) * 2008-07-18 2010-01-21 Novozymes A/S Treatment of rheumatoid arthritis with mammal beta defensins

Also Published As

Publication number Publication date
TW201004641A (en) 2010-02-01
AR072524A1 (es) 2010-09-01
MX2011000569A (es) 2011-02-23
EP2320929A2 (en) 2011-05-18
WO2010007165A2 (en) 2010-01-21
KR20110044863A (ko) 2011-05-02
EP2320929B1 (en) 2019-05-29
US20100016232A1 (en) 2010-01-21
AU2009272680A1 (en) 2010-01-21
CA2730674A1 (en) 2010-01-21
JP2011528332A (ja) 2011-11-17
ZA201100462B (en) 2013-03-27
KR20110031962A (ko) 2011-03-29
AP2011005537A0 (en) 2011-02-28
BRPI0915780A2 (pt) 2019-03-12
IL210714A0 (en) 2011-03-31
EA201170218A1 (ru) 2011-08-30
WO2010007165A3 (en) 2010-06-03
CN102159232A (zh) 2011-08-17
NZ590466A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
CL2012003385A1 (es) Tratamiento para la incontinencia.
HN2012000263A (es) Derivados n1-sulfonil-5-fluoropirimidinona
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
SV2010003593A (es) Nuevos herbicidas
CR11776A (es) Inhibidores de bace
CL2009001032A1 (es) Combinaciones de compuestos activos para controlar plagas animales; uso de las combinaciones; y procedimientos para controlar plagas animales.
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
ECSP12011581A (es) Inhibidores de bace
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
EA201270254A1 (ru) Производные 5-фторпиримидинона
UY33754A (es) Monobactamas
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
BRPI1008253A2 (pt) Metoso para tratar biomassa
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
CL2009001363S1 (es) Pieza para maquina de afeitar.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
CL2009001973S1 (es) Mostrador.